Metastatic Cancers: Clinical Trials

5 trials for Metastatic Cancers, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 active not recruiting, 1 suspended, 1 withdrawn. 5 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 25Recruiting 2, Active not recruiting 1, Suspended 1, Withdrawn 1
Phase 11Recruiting 1
Phase 31Recruiting 1

Follow Metastatic Cancers: new trials by email Literature Review of Metastatic Cancers trials Research Report on Metastatic Cancers

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
KRAS TCR-Transduced PBL, Aldesleukin, Fludarabine - Gastrointestinal Carcinoma, Pancreatic Cancer
Phase 2WithdrawnNational Cancer Institute (NCI)2025-09-092025-09-11
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
REC-1245 - Unresectable, Locally Advanced
Phase 1 / Phase 2RecruitingRecursion Pharmaceuticals Inc.1702024-11-212026-08-20
Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers
Psychoeducational Intervention, Open Label Placebo, Psychoeducational Intervention+Placebo - Metastatic Cancers, Fatigue
Phase 2 / Phase 3RecruitingM.D. Anderson Cancer Center2402024-02-162026-10-19
Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations
Vemurafenib - Solid Tumors, Hematologic Cancers
Phase 2Active not recruitingUNICANCER2162014-10-132025-08-01
Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas
Gene Modified T Cells - Metastatic Cancers
Phase 2SuspendedRoger Williams Medical Center482012-10-012016-06-14

Narrower conditions

Neoplasms (5)  ·  Colorectal Neoplasms (2)  ·  Cholangiocarcinoma (1)  ·  Duodenal Neoplasms (1)  ·  Fatigue (1)  ·  Liver Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Lymphoma (1)  ·  Neoplasm Metastasis (1)  ·  Pancreatic Neoplasms (1)  ·  Stomach Neoplasms (1)

Broader conditions

Colonic Diseases (2)  ·  Digestive System Diseases (2)  ·  Digestive System Neoplasms (2)  ·  Gastrointestinal Diseases (2)  ·  Gastrointestinal Neoplasms (2)  ·  Intestinal Diseases (2)  ·  Intestinal Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplasms by Site (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Rectal Diseases (2)  ·  Adenocarcinoma (1)  ·  Carcinoma (1)  ·  Duodenal Diseases (1)  ·  Endocrine Gland Neoplasms (1)

Interventions

Cyclophosphamide (1)  ·  Vemurafenib (1)  ·  aldesleukin (1)  ·  fludarabine (1)

Sponsors

M.D. Anderson Cancer Center (1)  ·  National Cancer Institute (NCI) (1)  ·  Recursion Pharmaceuticals Inc. (1)  ·  Roger Williams Medical Center (1)  ·  UNICANCER (1)

Countries

United States (4)  ·  Canada (1)  ·  France (1)

Top investigators

Jean-Yves PI Blay, MD (1)  ·  Nicholas D Klemen, M.D. (1)  ·  Richard P Junghans, PhD, MD (1)  ·  Sriram Yennu, MD (1)

Results publications

PMID 31959346

NIH funding

2014 (1)